Modern Biontech Stocks Vaccine Manufacturers, Divergent mRNA strategies

Covide-19 pandemic turned Modern And Biontech In familiar names almost overnight. Now the two companies are on different paths.

Moderna and Biontech helped pioneering mRNA technology, or messenger RNA. Moderna marked out its whole identity around mRNA, while Biontech saw it as an element of a wider portfolio focused on immunology and oncology. The pandemic gave the two companies a chance to prove the mRNA promise to use the body’s own immune system to protect itself against viruses or treat disease.

Covid vaccines have generated about $ 45 billion in sales for each company, which has each earned them about $ 20 billion since their deployment at the end of 2020. But despite parallel booms after the pandemic, vaccines have since taken their activities in various directions – and Wall Street has noticed.

The two companies have spent their vaccine manna covid differently: Moderna has doubled on her mRNA pipeline, while BionTech used money to make offers and diversify, especially in one of the hottest areas of cancer drugs. Today, Moderna has around 8.4 billion dollars in cash; Biontech based in Germany has 15.9 billion euros (or $ 18.2 billion).

The divergence of the two companies is even more striking in their performance in action. In the past year, Moderna shares have slipped around 72%; Biontech’s shares have won almost 29%.

“Just their name was made on the basis of the pandemic and the vaccines that they very quickly brought to people around the world to help us cross this period,” said Evercore Isi analyst Cory Kasimov. “But the approach they adopt now and the prospects of these two companies are clearly different at this stage.”

Investors will have a new overview of the performance of the two companies because they display quarterly results in the coming days. Moderna should report Friday morning, followed by Biontech on Monday morning.

Moderna did another step to reduce costs on Thursday because it announced that it would reduce around 10% of its workforce by the end of the year.

Moderna used her cocovated money to build her mRNA portfolio, especially vaccines. He has invested in shots for flu, RSV and less known viruses such as cytomegalovirus and norovirus.

“From our point of view, the pandemic has really shown that the science of what we do worked, and the kind of natural response was to continue on this path and to do more,” said Moderna president Stephen Hoge.

The financing of such an important pipeline was not cheap. The company began to reduce expenses while sales of its cocovio vaccine slide and RSV vaccine find it difficult to find foot. But the clock is running, said Leerink Man analyst Mani Foroohar.

“We are going in a time when being a vaccinations will be more expensive, tedious and expensive,” said Foroohar, citing changes to Food and Drug Administration under the direction of the Secretary of Health and Social Services Robert F. Kennedy Jr., who expressed skepticism about vaccines.

Forioohar in 2022 stressed what he considered a tragic Shakespearean flaw in the Moderna business model. This gap, in its opinion, is that Moderna has put its pipeline on the scale assuming that mRNA technology would be the tool for all problems instead of a solution for certain problems.

Hoge said that “really good for Moderna’s mRNA drugs” and decided to focus on this.

“The reality is that we are thinking in the past 10 years, that the objective has made us successful, and in the pandemic, it has certainly had a big impact and was obviously something that prepares us for the more diverse pipeline that we have at the moment,” said Hoge. “We therefore recognize that we can go through certain cycles, but we are quite confident in the long -term trajectory in which we are, and we are impatiently awaiting the years to come with all these additional drugs of which we are really capable of.”

In the meantime, BionTech decided to use the product of her vaccine cocorated to diversify. Outside the spotlights while the Pfizer partner took the lead to sell companies‘ Shot, Biontech has extended to new promising cancer technologies.

More importantly, he has acquired a bispecific antibody targeting PD-L1 and VEG-F proteins. This technology promises to rely on – and perhaps the best – the success that Merck has found with Keytruda, a cancer medication with nearly $ 30 billion in sales last year.

This thesis must still be proven in major global clinical trials, but Biontech already notes that the agreement was paying. Bristol Myers Squibb In June, he announced that it would pay up to 11 billion dollars to associate with Biontech to code the experimental medication, which Biontech acquired for a fraction of this. Biontech in 2023 initially paid for Biotheus $ 55 million in advance to obtain a license on medication outside of China before acquiring the company earlier this year for a maximum amount of $ 1 billion.

“”[BioNTech] I found an asset, they developed it, then they got a pharmaceutical partner, it’s like a dream, “said BMO analyst Evan David Seigerman.” They are really strategic, and I think they add a lot of diversification, which makes history much less risky if you are just concentrated on mRNA, vaccines and covid, and it is very risky, from my point of view. “”

At the same time, hopes are high that Biontech’s bispecific antibody medication will work, which means that any disappointment to come could harm the stock. Investors look at the results of the upcoming phase 3 trials of Summit Therapeutics, which tests a similar medication for lung cancer. This data could help – or hurt – Biontech’s actions while it awaits data from its own studies, which could take until 2028.

For Moderna, investors want to see if sales of her cocovated vaccines and RSV can bounce back. The company also requests the approval of the FDA for a vaccine against the mRNA flu. But at this stage, the most intense emphasis is on the Moderna phase 3 trial for personalized cancer treatment for melanoma, said Luca ISS of RBC capital market analyst.

Moderna can be able to share the first provisional data next year, said Hoge, although the company cannot promise an exact date because it is an event -focused study. This means that enough people in the trial should relapse before Moderna could analyze if her treatment prevented cancer from returning longer. If the treatment succeeds, it could be launched in 2027 or 2028, said Hoge.

This leaves modernized largely dependent on its vaccines until then. A COVVI-19 COVID-19 shot in progress could also eat in society In cash, analysts say, adding that they expect the legal proceedings to take place next year.

Time will tell us if the divergent strategies are gaining long term to Wall Street.